A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects

NCT02386436 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Scleroderma, Systemic

Interventions

DRUG: GSK2330811
DRUG: Placebo

Sponsor

GlaxoSmithKline